Background
• The purpose of this study is to evaluate the usefulness of certain compounds in the blood and urine as biomarkers for kidney disease. These biomarkers (KIM-1, SDMA, NGAL, or Cystatin C) may be able to alert us to acute kidney disease before our currently available biomarkers (creatinine) can alert us.

Participation Requirements
• Horses receiving medications that have potential kidney side effects like non-steroidal anti-inflammatory drugs (e.g., Banamine, phenylbutazone, Equioxx), aminoglycoside antibiotics (e.g., gentamicin or amikacin) or oxytetracycline
• A blood test and kidney ultrasound are required to ensure your horse does not already have kidney alterations and determine eligibility.

Procedures
• We will collect blood and urine daily and repeat the kidney ultrasound on the last day of relevant medication administration to monitor biomarkers of kidney function.

Owner Responsibilities
• Cover the costs of your horse’s required hospitalization and associated treatments
• Keep all scheduled appointments

Benefits
• The study will cover all costs associated with the study, including the kidney ultrasound and the sample collections of blood and urine, and cover medical treatment for phlebitis (inflammation of the vein that occurs rarely with blood collections), if your horse develops this condition while participating in the study.
• Your horse will receive a full kidney ultrasound, which could detect early kidney disease if indicated.

PRINCIPAL INVESTIGATORS
Dr. Emily Schaefer
Dr. Monica Aleman • Dr. Mary Lassaline

CONTACT INFORMATION
easchaefer@ucdavis.edu • (717) 329-2132
mraelman@ucdavis.edu • (530) 752-0290
lassaline@ucdavis.edu • (530) 752-0290

Call (530) 752-0290 to make an appointment with the Large Animal Clinic

www.vetmed.ucdavis.edu/clinicaltrials/